1. Home
  2. RELY vs MLYS Comparison

RELY vs MLYS Comparison

Compare RELY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Remitly Global Inc.

RELY

Remitly Global Inc.

HOLD

Current Price

$13.77

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$32.32

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RELY
MLYS
Founded
2011
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.1B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
RELY
MLYS
Price
$13.77
$32.32
Analyst Decision
Buy
Strong Buy
Analyst Count
10
7
Target Price
$26.00
$47.33
AVG Volume (30 Days)
2.5M
1.5M
Earning Date
02-18-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$1,544,865,000.00
N/A
Revenue This Year
$30.78
N/A
Revenue Next Year
$18.57
N/A
P/E Ratio
$145.89
N/A
Revenue Growth
31.27
N/A
52 Week Low
$12.08
$8.24
52 Week High
$27.32
$47.65

Technical Indicators

Market Signals
Indicator
RELY
MLYS
Relative Strength Index (RSI) 49.60 33.20
Support Level $13.06 $31.67
Resistance Level $13.88 $33.64
Average True Range (ATR) 0.41 1.67
MACD 0.00 -0.23
Stochastic Oscillator 55.07 19.56

Price Performance

Historical Comparison
RELY
MLYS

About RELY Remitly Global Inc.

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: